For Roche, the future is personalised. Fitting the treatment to the patient is an ambitious goal - but the concept of personalised healthcare is at the heart of our research and development strategy in cancer. Through this approach, we aim to use new molecular insights and molecular diagnostic tests to provide more tailored medicines and enhance the management of cancer.
Research into diagnostics will continue, and biomarkers (components of our body cells that can be used as indicators for the disease) will enable doctors to determine much more quickly and specifically which cancer type a patient has. Roche is already working to identify tumour markers that will detect tumour cells long before the first symptoms become apparent.
We are already further developing our cobas® AmpliChip® P53 test, which will enable doctors to make a more specific prognosis for cancer patients.
Our scientists will also continue to target the processes that lead to the disease. Biopharmaceuticals, especially highly specific antibodies, will play an important role in the future. Each day around 7,000 scientists work for Roche on developing new medicines for diseases including cancer.
We have a rich pipeline of new products, with global and UK based development teams managing international and local clinical trials working towards new treatments for cancer. Over 235,400 people took part in our clinical trials worldwide in 2008, receiving access to the latest treatments for diseases including cancer. Currently in oncology alone we have a staggering 1387 active Phase I to Phase IV clinical trials across the world.
Ultimately, our goal is to use modern technologies to provide healthcare professionals with more powerful diagnostic tools and even more effective biopharmaceutical treatments based on new insights into how cancer arises at the molecular level.